I M Robbins
Overview
Explore the profile of I M Robbins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaver C, Castilho J, Cohen D, Grogan E, Miller G, Dummer J, et al.
Am J Transplant
. 2014 Nov;
14(12):2893-7.
PMID: 25376207
Seventeen days after double lung transplantation, a 56-year-old patient with idiopathic pulmonary fibrosis developed respiratory distress. Imaging revealed bilateral pulmonary infiltrates with pleural effusions and physical examination demonstrated sternal instability....
2.
Austin E, Rock M, Mosse C, Vnencak-Jones C, Yoder S, Robbins I, et al.
Respir Med
. 2009 Nov;
104(3):454-62.
PMID: 19880300
Rationale: Mounting data suggest that immune cell abnormalities participate in the pathogenesis of pulmonary arterial hypertension (PAH). Objective: To determine whether the T lymphocyte subset composition in the systemic circulation...
3.
Robbins I, Kawut S, Yung D, Reilly M, Lloyd W, Cunningham G, et al.
Eur Respir J
. 2006 Mar;
27(3):578-84.
PMID: 16507859
Idiopathic pulmonary arterial hypertension (IPAH) is characterised by in situ thrombosis and increased thromboxane (Tx) A2 synthesis; however, there are no studies of antiplatelet therapy in IPAH. The aim of...
4.
Frost A, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, et al.
Vascul Pharmacol
. 2005 May;
43(1):36-9.
PMID: 15890561
Background: PAH trials traditionally use 6MW as the primary endpoint. Concerns regarding a "ceiling effect" masking efficacy have led to exclusion of patients with milder disease from most trials (BL...
5.
Humbert M, Barst R, Robbins I, Channick R, Galie N, Boonstra A, et al.
Eur Respir J
. 2004 Sep;
24(3):353-9.
PMID: 15358690
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated....
6.
Bresser P, Fedullo P, Auger W, Channick R, Robbins I, Kerr K, et al.
Eur Respir J
. 2004 Apr;
23(4):595-600.
PMID: 15083760
Pathophysiological findings in chronic thromboembolic pulmonary hypertension (CTEPH) have suggested that a secondary small vessel arteriopathy may contribute to the haemodynamic impairment observed in these patients. It was hypothesised that...
7.
Harrison R, Flanagan J, Sankelo M, Abdalla S, Rowell J, Machado R, et al.
J Med Genet
. 2003 Dec;
40(12):865-71.
PMID: 14684682
Background: Mutations of the transforming growth factor beta (TGFbeta) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT). Heterozygous mutations of the type II...
8.
Robbins I, Davis A, Doyle T, Loyd J
Chest
. 2001 Nov;
120(5):1750-1.
PMID: 11713170
No abstract available.
9.
Robbins I, Barst R, Rubin L, Gaine S, Price P, Morrow J, et al.
Chest
. 2001 Nov;
120(5):1639-44.
PMID: 11713147
Study Objective: TXA(2) (thromboxane A(2)) is a lipid mediator believed to be produced primarily by platelets in normal subjects, although macrophages are capable of synthesis. There is increased production of...
10.
Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V, et al.
Lancet
. 2001 Oct;
358(9288):1119-23.
PMID: 11597664
Background: Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can...